Navigation Links
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Date:11/5/2008

SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following investor conferences in November.

Rodman & Renshaw 10th Annual Healthcare Conference

New York Palace Hotel

Wednesday, November 12, 2008

9:55 a.m. ET

Lazard Capital Markets 5th Annual Healthcare Conference

The St. Regis Hotel, New York

Tuesday, November 18, 2008

8:55 a.m. ET

The presentations will be audio webcast live and available for replay from Dendreon's website, http://www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
2. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
3. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
4. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
5. Dendreon Reports First Quarter 2008 Financial Results
6. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
7. Dendreon Announces Closing of Registered Direct Offering
8. Dendreon Announces $47 Million Registered Direct Offering
9. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...
(Date:12/7/2016)... NE (PRWEB) , ... December 07, 2016 , ... ... systems integration, today announced that it has become a Wonderware Certified System Integrator ... System Integrator Partner by Schneider Electric Software. , “The System Integrator Partner certification ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
Breaking Biology Technology:
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported ... to over 40 granted and pending patents. ... , The Company,s IP portfolio ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... hardware components needed to estimate the force and pressure applied to touch ...
(Date:12/7/2016)... Dec. 7, 2016   Avanade is helping ... One teams in history, exploit biometric data in order ... and maintain the competitive edge against their rivals after ... Avanade has worked with Williams during the ... biometric data (heart rate, breathing rate, temperature and peak ...
Breaking Biology News(10 mins):